Lausanne-based Vandria presented multiple ascending-dose Phase 1 data for oral small molecule VNA-318 at the Alzheimer’s Association International Conference in London.
According to the company, 12 days of dosing produced pharmacodynamic effects on brain activity measured by quantitative EEG, including reduced alpha-band activity, and direct measurement of VNA-318 in cerebrospinal fluid confirmed brain penetration.
Post-hoc analyses of plasma and intracellular metabolites linked to energy metabolism and fatty acid oxidation were consistent with preclinical neurodegeneration models.
Earlier topline results reported in December 2025 showed favorable safety and tolerability with no serious adverse events or discontinuations, and pharmacokinetic findings demonstrated a half-life supportive of once-daily oral dosing and a predictable, dose-linear increase in exposure at concentrations considered therapeutic in preclinical studies.
The randomized, double-blind, single- and multiple-ascending-dose trial enrolled 92 healthy male subjects.
Vandria positions VNA-318 as a mitochondrial-restorative agent that may reduce chronic neuroinflammation and intends to advance clinical development with alzheimer’s disease as the initial indication.
